Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) announced on November 18, 2026, that all matters put before shareholders at its annual general meeting were approved. A total of 2,824,597 common shares were voted, representing 34.93% of the 8,086,889 shares issued and outstanding as of the record date. The confirmed outcomes include director elections and approval of the company's equity incentive plan, providing governance clarity for investors monitoring the oral stimulant pouch company.
Key Points
- Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) held its annual general meeting on November 18, 2026
- All matters were approved, including director elections and the omnibus equity incentive compensation plan
- 2,824,597 common shares voted, representing 34.93% of 8,086,889 shares outstanding at the record date
- Investors may be watching for further operational updates following the confirmed board and governance structure
Doseology Board of Directors Elected at November 2026 AGM
Shareholders elected three directors at the meeting: Kareem Baalbaki, Jeremy Wright, and Scott Reeves. The release does not indicate whether any of these individuals are newly appointed or continuing directors. Baalbaki is identified as Interim CEO on behalf of the Board of Directors. The confirmed board composition provides investors with visibility into the leadership structure guiding Doseology Sciences as the company operates within the growing oral stimulant pouch category.
Auditor Reappointment and Equity Incentive Plan Confirmed
Shareholders also approved two additional resolutions at the meeting. Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants, was reappointed as the company's auditor. Additionally, the company's omnibus equity incentive compensation plan was approved in accordance with the requirements of the Canadian Securities Exchange. The equity incentive plan is a common governance mechanism used by listed companies to align management and employee interests with those of shareholders over the longer term.
Doseology's Position in the Oral Stimulant Pouch Market
Doseology Sciences specialises in pouch-based oral stimulant and cognitive support products. The company describes the oral pouch sector as one of the most dynamic and high-growth areas in modern functional consumer products, with consumers increasingly prioritising convenience, portability, and format innovation. The release states that oral stimulant pouches are smokeless and vapour-free, positioning them as an alternative to combustible tobacco and vape products. The immediate share price impact was not clear from available public information.



Please wait processing your request...